Agios Pharmaceuticals, Inc. (AGIO)
$
37.01
+0.33 (0.89%)
Key metrics
Financial statements
Free cash flow per share
-7.0604
Market cap
2.2 Billion
Price to sales ratio
52.6076
Debt to equity
0.0356
Current ratio
14.4790
Income quality
-0.6245
Average inventory
30.2 Million
ROE
0.4331
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Agios Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering and developing medicines within the realm of cellular metabolism and related biological areas. The company delivers pivotal treatments such as PYRUKYND (mitapivat), an activator for both wild-type and various mutant pyruvate kinase (PK) enzymes targeted at addressing hemolytic anemias. Additionally, Agios is advancing AG-946, currently in Phase I clinical studies for treating hemolytic anemias and other medical indications. Financially, the company earned an interest income of $48,083,000.00 showcasing its strategic financial investments. The income before tax ratio is 19.67 reflecting the pre-tax margin and indicating a robust operational capacity. However, the net total of other income and expenses is $1,143,706,000.00 which illustrates the influence of non-core financial activities on the overall financial picture. Moreover, the company reported depreciation and amortization expenses of $5,653,000.00 which reflect the wear and tear of its physical and intangible assets. The gross profit ratio is 0.89 indicating the efficiency of the company's production and sales operations in maintaining profitability while advancing its innovative drug portfolio. As a notable entity in the biopharmaceutical landscape, Agios Pharmaceuticals operates within a mid-range market capitalization of $2,150,336,515.00 positioning itself as a steady performer in the industry. The stock is affordable at $39.23 making it suitable for budget-conscious investors looking to engage in this sector. Additionally, the stock has an average trading volume of 742,696.00 indicating moderate liquidity, which is essential for investors considering market entry. It is a key player in the biopharmaceutical industry, contributing significantly to the overall market landscape and driving forward innovation and growth. Positioned within the Healthcare sector, Agios Pharmaceuticals reflects a commitment to advancing healthcare solutions while fostering economic stability through its strategic investment and operational initiatives.
Is Agios Pharmaceuticals, Inc. (AGIO) a good investment?
Investing in Agios Pharmaceuticals, Inc. (AGIO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A-, with a Bearish outlook. Always conduct your own research before investing.
What is Agios Pharmaceuticals, Inc. (AGIO)'s stock forecast?
Analysts predict Agios Pharmaceuticals, Inc. stock to fluctuate between $23.42 (low) and $62.58 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Agios Pharmaceuticals, Inc.'s market capitalization?
As of 2025-08-15, Agios Pharmaceuticals, Inc.'s market cap is $2,150,336,515, based on 58,101,500 outstanding shares.
How does Agios Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Agios Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Agios Pharmaceuticals, Inc. (AGIO) stock?
To buy Agios Pharmaceuticals, Inc. (AGIO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AGIO. Place an order (Market, Limit, etc.).
What is the best time to invest in Agios Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Agios Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $36,498,000 | EPS: $11.86 | Growth: -287.36%.
Where can I find Agios Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.agios.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Agios Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Agios Pharmaceuticals, Inc. stock?
All-time high: $62.58 (2024-11-11) | All-time low: $16.75 (2022-06-16).
What are the key trends affecting Agios Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
fool.com
Agios Pharmaceuticals (AGIO -6.15%), a biotechnology company focused on therapies for rare blood disorders, released its second quarter 2025 earnings on July 31, 2025. The headline was a notable revenue beat: This quarter showcased clear progress on sales for its lead product PYRUKYND, with GAAP net product revenue of $12.5 million, yet also highlighted the company's increasing cost base as it prepares for major regulatory events and launches.
seekingalpha.com
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q2 2025 Earnings Call July 31, 2025 8:00 AM ET Company Participants Brian M. Goff - CEO & Director Cecilia Jones - Chief Financial Officer Sarah Gheuens - Chief Medical Officer and Head of Research & Development Tsveta Milanova - Chief Commercial Officer Morgan Sanford - Vice President, Investor Relations Conference Call Participants Andrew Scott Berens - Leerink Partners LLC, Research Division Emily Claudia Bodnar - H.C.
zacks.com
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.93 per share versus the Zacks Consensus Estimate of a loss of $1.74. This compares to a loss of $1.69 per share a year ago.
globenewswire.com
$12.5 million in second quarter PYRUKYND® (mitapivat) net revenues; ended second quarter with $1.3 billion dollars in cash, cash equivalents and marketable securities PYRUKYND sNDA for thalassemia under active review, with FDA PDUFA goal date of September 7, 2025 Topline results from RISE UP Phase 3 trial of mitapivat in sickle cell disease on track by year-end with potential U.S. commercial launch in 2026 Dosed first patient in the tebapivat Phase 2 sickle cell disease trial and received IND clearance for AG-236 CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and updates for the second quarter ended June 30, 2025.
globenewswire.com
CAMBRIDGE, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, July 31, 2025, at 8:00 a.m.
businesswire.com
AMSTERDAM--(BUSINESS WIRE)-- #biotech--Avanzanite Bioscience B.V. (“Avanzanite”), a fast-growing commercial-stage specialty pharmaceutical company dedicated to bringing rare disease medicines to patients across Europe, announced today an exclusive agreement with Agios Pharmaceuticals Inc. (Nasdaq: AGIO), a Boston-based biotech company focused on the development and commercialization of rare disease medicines. Under the agreement, Avanzanite will commercialize and distribute PYRUKYND® (mitapivat) across th.
zacks.com
AGIO's earnings beat estimates in the first quarter of 2025, while revenues miss the same.
zacks.com
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.55 per share versus the Zacks Consensus Estimate of a loss of $1.80. This compares to loss of $1.45 per share a year ago.
globenewswire.com
– U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND ® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with Topline Results Expected in Late 2025; Potential U.S. Commercial Launch in 2026 – – Tebapivat Advancing in Clinical Trials for Lower-Risk Myelodysplastic Syndromes (LR-MDS) and Sickle Cell Disease – – PYRUKYND Net Revenue of $8.7 Million in Q1; Cash, Cash Equivalents and Marketable Securities of $1.4 Billion as of March 31, 2025 – CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today reported business highlights and financial results for the first quarter ended March 31, 2025.
zacks.com
AGIO, CHGG and EFX have been added to the Zacks Rank #5 (Strong Sell) List on April 3, 2025.
See all news
